Abeona Therapeutics Inc.
ABEONASDAQHealthcare● Active
$5.38
$-0.08(-1.47%)
Market Cap$306633875
P/E Ratio—
52W High$7.54
52W Low$4
Abeona Therapeutics Inc. (ABEO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ABEO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.30
Est. -$0.33 · +9.1%
Revenue
$0.01B
Est. $0.00B · +90.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 7-Quarter EPS Beat Streak
ABEO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.02
Rev. $0.33B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.02
Rev. Est.$0.33B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.23 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.33 | -$0.30 | +9.1% | $0.01B | $0.00B | +90.7% |
| ▲ Q1 FY2026 | Mar 17, 2026 | -$0.35 | -$0.34 | +2.9% | $0.01B | $0.00B | +22.1% |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.27 | -$0.10 | +63.0% | — | $0.01B | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.39 | $1.71 | +538.5% | $0.00B | $0.01B | -93.9% |
| ▲ Q2 FY2025 | May 15, 2025 | -$0.35 | -$0.24 | +31.4% | — | — | — |
| ▲ Q1 FY2025 | Mar 20, 2025 | -$0.43 | -$0.24 | +44.2% | — | $0.00B | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$0.38 | -$0.31 | +18.4% | — | $0.00B | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.23
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.30
EPS Est.
-$0.33
EPS Surpr.
+9.1%
Revenue
$0.01B
Q1 FY2026
Mar 17, 2026Beat
EPS Actual
-$0.34
EPS Est.
-$0.35
EPS Surpr.
+2.9%
Revenue
$0.01B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.10
EPS Est.
-$0.27
EPS Surpr.
+63.0%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
$1.71
EPS Est.
-$0.39
EPS Surpr.
+538.5%
Revenue
$0.00B
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$0.24
EPS Est.
-$0.35
EPS Surpr.
+31.4%
Revenue
—
Q1 FY2025
Mar 20, 2025Beat
EPS Actual
-$0.24
EPS Est.
-$0.43
EPS Surpr.
+44.2%
Revenue
—
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.31
EPS Est.
-$0.38
EPS Surpr.
+18.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.07 | $0.10 | $0.15 | 1 |
| Q3 FY2027 | $0.03 | $0.04 | $0.06 | 1 |
| Q2 FY2027 | $0.00 | $0.00 | $0.00 | 1 |
| Q1 FY2027 | $-0.07 | $-0.05 | $-0.03 | 1 |
| Q4 FY2026 | $-0.12 | $-0.08 | $-0.05 | 1 |
| Q3 FY2026 | $-0.24 | $-0.13 | $-0.01 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.1B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.1B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +9.1% | $5.68 | $5.71 | +0.53% |
| ▲ Q1 FY2026 | Mar 17, 2026 | +2.9% | $4.95 | $4.76 | -3.84% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +63.0% | $4.17 | $4.94 | +18.47% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +538.5% | $6.56 | $7.23 | +10.21% |
| ▲ Q2 FY2025 | May 15, 2025 | +31.4% | $5.39 | $5.79 | +7.42% |
| ▲ Q1 FY2025 | Mar 20, 2025 | +44.2% | $5.20 | $5.14 | -1.15% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +18.4% | $6.10 | $5.95 | -2.46% |
| ▼ Q3 FY2024 | Aug 12, 2024 | -127.3% | $4.42 | $4.95 | +11.99% |
Q2 FY2026+0.53%
Report Date
May 13, 2026
EPS Beat/Miss
+9.1%
Price Before
$5.68
Price After
$5.71
Q1 FY2026-3.84%
Report Date
Mar 17, 2026
EPS Beat/Miss
+2.9%
Price Before
$4.95
Price After
$4.76
Q4 FY2025+18.47%
Report Date
Nov 12, 2025
EPS Beat/Miss
+63.0%
Price Before
$4.17
Price After
$4.94
Q3 FY2025+10.21%
Report Date
Aug 14, 2025
EPS Beat/Miss
+538.5%
Price Before
$6.56
Price After
$7.23
Q2 FY2025+7.42%
Report Date
May 15, 2025
EPS Beat/Miss
+31.4%
Price Before
$5.39
Price After
$5.79
Q1 FY2025-1.15%
Report Date
Mar 20, 2025
EPS Beat/Miss
+44.2%
Price Before
$5.20
Price After
$5.14
Q4 FY2024-2.46%
Report Date
Nov 14, 2024
EPS Beat/Miss
+18.4%
Price Before
$6.10
Price After
$5.95
Q3 FY2024+11.99%
Report Date
Aug 12, 2024
EPS Beat/Miss
-127.3%
Price Before
$4.42
Price After
$4.95
Avg Beat Reaction+4.17%
Avg Miss Reaction+11.99%
Beat Rate7 / 8 quarters
Largest Move+18.47% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ABEO ends December
Abeona Therapeutics Inc. (ABEO) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.30 — beating the analyst consensus of $-0.33 by +9.1%. ABEO has beaten EPS estimates for 7 consecutive quarters. The next ABEO earnings date is expected around September 1, 2026.
Each quarter, investors track ABEO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ABEO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ABEO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ABEO earnings · 5 questionsAbeona Therapeutics Inc.'s next earnings report is expected around September 1, 2026. ABEO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ABEO historically reports after market close (AMC).
ABEO earnings datewhen is ABEO earningsABEO next earnings datewhen does ABEO report earningsABEO earnings calendar
▸ Source: FMP · Abeona Therapeutics Inc. SEC filings · US GAAP · Abeona Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026